Page 1

Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results ir.acadia-pharm.com/news-releases/news-release-details/acadia-pharmaceuticals-reports-first-quarter-2021 financial Press Release Acadia - 1Q21 net sales of $ 106.6 million , an 18 % increase over 1Q20 - Reiterating FY21 net sales guidance of $ 510 to $ 550 million Acadia Pharmaceuticals Inc. ( Nasdaq : ACAD ) , today announced its financial results for the first quarter ended March 31 , 2021 . " NUPLAZID delivered strong year - over - year performance in the first quarter of 2021 . Looking ahead , we see positive signs in the Parkinson's disease psychosis market supporting revenue growth for the remainder of the year as we anticipate continued improvements in the conditions related to the pandemic , ” said Steve Davis , Chief Executive Officer . " Furthermore , we look forward to a Type A meeting with the FDA to discuss an approval path for pimavanserin in dementia - related psychosis and we continue to advance our two Phase 3 programs for Rett syndrome and the negative symptoms of schizophrenia , as well as our Phase 2 pain program and earlier pipeline opportunities . " Company Updates The Company received a Complete Response Letter ( CRL ) from the U.S. Food and Drug Administration ( FDA ) regarding its supplemental New Drug Application ( SNDA ) for NUPLAZIDⓇ ( pimavanserin ) for the treatment of hallucinations and delusions associated with dementia - related psychosis ( DRP ) . The Company plans to conduct a Type A meeting with the FDA to discuss the CRL and potential next steps to support an approval . 1/7